# AMER1

Source: https://onco.cc/targets/amer1/  
OnCo record `amer1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AMER1 (APC membrane recruitment protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Skin cancer, Leukaemia and 3 more.

## Summary

Regulator of the canonical Wnt signalling pathway. Acts by specifically binding phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), translocating to the cell membrane and interacting with key regulators of the canonical Wnt signalling pathway, such as components of the beta-catenin destruction complex. Acts both as a positive and negative regulator of the Wnt signalling pathway, depending on the context: acts as a positive regulator by promoting LRP6 phosphorylation.

Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes affected pathway 0.92, literature 0.90, genetic association 0.77, somatic mutation 0.97, animal model 0.41). IntOGen calls it a driver in 9 cohorts (0 activating, 9 loss-of-function), covering Colon Adenocarcinoma, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Wilms' Tumour.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: APC membrane recruitment protein 1; RP11-403E24.2; FLJ39827; FAM123B
- Tags: cancer-genes-wave
- Symbol: AMER1
- Class: tumor-suppressor
- Biology: Regulator of the canonical Wnt signalling pathway. Acts by specifically binding phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), translocating to the cell membrane and interacting with key regulators of the canonical Wnt signalling pathway, such as components of the beta-catenin destruction complex. Acts both as a positive and negative regulator of the Wnt signalling pathway, depending on the context: acts as a positive regulator by promoting LRP6 phosphorylation. Also acts as a negative regulator by acting as a scaffold protein for the beta-catenin destruction complex and promoting stabilisation of Axin at the cell membrane. Promotes CTNNB1 ubiquitination and degradation. Involved in kidney development. Location: Cytoplasm; Cell membrane; Nucleus (UniProt). Locus Xq11.2 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.75 with colorectal cancer (MONDO_0005575); IntOGen driver in 7 cohorts (COAD, COADREAD); Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898); Leukaemia: Open Targets association 0.50 with leukaemia (MONDO_0005059); Rectal cancer: IntOGen driver in 1 cohort (READ); Wilms tumour: IntOGen driver in 1 cohort (WT); Melanoma: Open Targets association 0.54 with melanoma (MONDO_0005105)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 9 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:26837: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26837
- UniProt Q5JTC6: https://www.uniprot.org/uniprotkb/Q5JTC6/entry
- NCBI Gene 139285: https://www.ncbi.nlm.nih.gov/gene/139285
- Ensembl ENSG00000184675: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184675

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Melanoma](https://onco.cc/cancers/melanoma/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Wilms tumour (nephroblastoma)](https://onco.cc/cancers/wilms-tumor/)

---
JSON: https://onco.cc/api/v1/entities/amer1.json